Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Overview of attention for article published in New England Journal of Medicine, January 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

news: 27 news outlets
blogs: 1 blog
policy: 3 policy sources
twitter: 122 X users
patent: 22 patents

facebook: 3 Facebook pages
wikipedia: 1 Wikipedia page
video: 1 YouTube creator
guideline: 4 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 483 Mendeley

So far, Altmetric has seen 3 public wall posts from 3 users.

Scientific Information & News, 10 Jan 2020

Luspatercept is a fusion protein aimed at binding TGF-β family members and reducing SMAD2 and SMAD3 signaling in patients with…

Dr. Alexandre Mello de Azevedo - Hematologista, 09 Jan 2020

Mais um agente alvo-específico interessante. Bons resultados em talassemias e, agora, síndromes mielodisplásicas.

The New England Journal of Medicine, 09 Jan 2020

Luspatercept is a fusion protein aimed at binding TGF-β family members and reducing SMAD2 and SMAD3 signaling in patients with…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity.